GlassScriptPhysician profile
Michel Zakari
NPI 1750361093
$6,201.65
in general payments reported to CMS, 2019-2025
27 companies · $642 in 2025
The $642 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,390 · 2020: $446 · 2021: $1,222 · 2022: $826 · 2023: $844 · 2024: $832 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,293 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,293.44 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $810.44 | 2019-2025 | Lokelma, Farxiga |
| Aurinia Pharma U.S., INC. | $639.39 | 2021-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $570.10 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $524.69 | 2019-2025 | Parsabiv, Tavneos, Krystexxa |
| Akebia Therapeutics INC | $464.73 | 2019-2025 | Vafseo, Auryxia |
| Fresenius USA Marketing, INC. | $458.75 | 2019-2025 | Velphoro, Velphoro |
| Mallinckrodt Hospital Products INC. | $383.49 | 2020-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $283.17 | 2021-2023 | |
| Horizon Therapeutics Plc | $258.57 | 2019-2022 | |
| Glaxosmithkline, LLC. | $252.57 | 2021-2025 | Benlysta, Jesduvroq |
| Vifor Pharma, INC. | $222.31 | 2019-2025 | Veltassa |
| Alexion Pharmaceuticals, INC. | $201.04 | 2019 | |
| Opko Pharmaceuticals, LLC | $185.33 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $165.35 | 2021-2025 | |
| Novo Nordisk INC | $143.04 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $123.40 | 2024 | |
| Baxter Healthcare | $121.37 | 2022 | |
| Amarin Pharma, INC. | $76.08 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.54 | 2019-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.99 | 2024-2025 | Jardiance |
| Mallinckrodt Enterprises LLC | $51.65 | 2019 | |
| Calliditas Therapeutics US INC. | $43.74 | 2022-2023 | Tarpeyo |
| Nuwellis, INC. | $34.39 | 2021 | |
| Ani Pharmaceuticals, INC. | $22.60 | 2023 | Purified Cortrophin Gel |
| Xeris Pharmaceuticals, INC. | $14.34 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.58 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michel Zakari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.